Get your full text copy in PDF
Małgorzata Muc-Wierzgon, Janusz Wierzgon, Katarzyna Madej, Marek Baranowski
Med Sci Monit 1999; 5(3): CR519-523
In order to identify' immunologic parameters of prognostic value, we studied changes in immune responses during first cycle of treatment with hrec TNF alpha. The study consisted of 21 patients with locally advanced or metastasis solid tumor (M/F: 12/9 median age, mean 57 years. 38-65) for whom standard therapy was available. Clinical responses were assessed by physical examination, serum markers, computerized tomographic scans of the chest and abdomen, chest X-ray and bone scans every 4 to 8 weeks. The toxicity of TNF was mild in all patients.